Table 1.
Patient anticancer therapy (ACT) regimens March 1 to June 30, 2020.
| Type | Treatment | Steroid | Standard duration (days) | Cycles | Patients |
|---|---|---|---|---|---|
| IO | Atezoliazumab | — | — | 51 | 12 |
| IO | Pembrolizumab | — | — | 8 | 2 |
| CHEMO | Carbo/Etoposide | DEX | 3 | 7 | 2 |
| CHEMO | Cis1/Gem1 + 8 | DEX | 3 | 17 | 6 |
| CHEMO | Cis1 + 8/Gem1 + 8 | DEX | 3 | 33 | 15a |
| CHEMO | Docetaxel | DEX/PRED | 3/21 | 28 | 10 |
| CHEMO | Gemc/Carbo | DEX | 3 | 7 | 3 |
| CHEMO | Paclitaxel | DEX | 3 | 7 | 2a |
| TRIAL | POTOMAC (Durvalumab) | — | — | 18 | 4 |
| TRIAL | JAVELIN (Avelumab) | — | — | 4 | 1 |
| TRIAL | NIAGARA (Cis/Gem) | — | — | 5 | 2 |
| TRIAL | STRONG (Durvalumab) | — | — | 4 | 1 |
| TRIAL | ASTELLAS (Enfortumab) | — | — | 4 | 1 |
| TRIAL | ASTELLAS (Paclitaxel) | DEX | 3 | 2 | 1 |
| Total | — | — | — | 195 | 61a |
Duration of steroid in days. Patients receiving treatment on the ASTELLAS trial are presented by treatment type.
DEX dexamethasone, PRED prednisolone, IO immunotherapy, CHEMO chemotherapy, TRIAL patients receiving treatment on treatment on existing clinical trials.
aOne patient received two treatments (Paclitaxel followed by Cis1 + 8/Gem1 + 8), making a total of 61 patients.